Investors placed £731m into Venture Capital Trusts (VCTs) last year and early indications suggest that they may top that this year. The reason is simple – many of us now use VCTs as a key part of retirement planning alongside … Continued

Investors placed £731m into Venture Capital Trusts (VCTs) last year and early indications suggest that they may top that this year. The reason is simple – many of us now use VCTs as a key part of retirement planning alongside … Continued
70 of the most promising high-growth tech firms in the UK have been named as the country’s top scaleup companies by tech group Silicon Valley Comes to the UK (SVC2UK). The chosen scaleups – fast-growing companies that have expanded beyond the … Continued
genedrive’s genetic screening test could prevent thousands of infants from needlessly going deaf. genedrive plc, the near patient molecular diagnostics company, announced that its Antibiotic Induced Hearing Loss test, the Genedrive® MT-RNR1 ID kit, has obtained CE marking. The Genedrive® … Continued
MIP Diagnostics Ltd, the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, has announced a collaborative agreement with commercial partners for the co-development and license of a novel MIP-based system with specific applications in the security field. The long-term … Continued
New research finds that if active managers had the discipline to avoid clinging to their positions for too long, they could easily beat index funds. Love affairs are exciting in their early stages — but in stocks, as in life, … Continued
Calculus Capital is pleased to announce the appointment of Dominic Harris as Portfolio Management Director. Dominic was previously an Investment Director at Valtegra, a private equity firm focused on the investment in and turnaround of mid-market companies facing unique situational … Continued
Tax-efficient international exposure can be found beyond the FTSE 100. In the wake of Brexit we have seen many fund managers extolling the virtue of a portfolio heavily dominated by FTSE 100 companies. The argument in their favour is that … Continued
Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings. Mologic said it will invest a part of an … Continued